Aripiprazole LA-Partial agonist
From Psychiatrienet
| ||||||||||||||||||||||||||
| {{:Partial agonist[1] }} | ||||||||||||||||||||||||||
Switch medication from Aripiprazole LA to Partial agonist[1].[2]
[3]
Partial agonist is a collection of antipsychotic drugs having similar properties with respect to switching. A switch to member of the 'partial agonist' group from anotherdrug should be read as partial agonist-anotherdrug. Similarly, a switch from a member of the 'partial agonist' group to anotherdrug should be read as anotherdrug-partial agonist.
Stop Aripiprazole LA - Day 1: Last depot injection
Start Partial agonist[1]- t= 0 Start dosing 25% of the target dose on the day you normally would have injected the former depot.
- t= 1 x T1/2 of depot approx. 50% of target dose
- t= 2 x T1/2 of depot approx. 75% of target dose
- t= 3 x T1/2 of depot approx. 100% of target dose
- See 'more information' for the T1/2 of this depot
- the T1/2 of aripiprazole depot is 46.5 days after administration of 400 mg and approximately 29.9 days after adminstration of 300 mg.[4]
More information- More information you'll find in the summary of product characteristics (SPC) of aripiprazole depot injection. [5]
- ↑ A. Risselada, Switchen van en naar depotantipsychotica - een update; Psyfar, june 2022 nummer 2
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ KNMP Kennisbank, informatorium medicamentorum: Aripiprazol
- ↑ http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002755/WC500156111.pdf SPC of the European Medicines Agency on aripiprazole depot
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
[[Category:SwitchPartial agonist[1]]]
